Nautilus Biotechnology, Inc. (NAUT) Financial Statements
Industry: Laboratory Analytical Instruments
In fiscal 2025, Nautilus Biotechnology reported revenue of $0. Net income was -$59.0M, or -$0.47 per diluted share. Operating activities generated -$50.7M of cash, leaving -$52.0M of free cash flow. At fiscal year end, Nautilus Biotechnology held $191.1M in total assets against $34.1M in total liabilities, including $12.4M of cash and equivalents.
Open the full interactive Nautilus Biotechnology financials → Quarterly statements, key ratios, valuation history and price charts.
Nautilus Biotechnology Key Stats
| Share Price | $2.05 |
|---|---|
| Market Cap | $260.6M |
| 52-Week Range | $0.85 – $3.95 |
| Shares Outstanding | 127.1 million (basic, 2026 Q2) |
Nautilus Biotechnology Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Goods Sold | $0 | — | — | — | — | — |
| Gross Profit | $0 | — | — | — | — | — |
| Pre-Tax Income | $0 | -$50.3M | -$57.9M | -$63.7M | -$70.8M | -$59.0M |
| Income Tax | — | $0 | $0 | $0 | $0 | $0 |
| Net Income | $0 | -$50.3M | -$57.9M | -$63.7M | -$70.8M | -$59.0M |
| Diluted EPS | — | -$0.60 | -$0.46 | -$0.51 | -$0.56 | -$0.47 |
Nautilus Biotechnology Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $190,000 |
| Net Income | -$13.6M | -$13.8M | -$14.7M | -$14.5M |
| Diluted EPS | -$0.11 | -$0.11 | -$0.12 | -$0.11 |
Nautilus Biotechnology Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | — | $185.6M | $114.5M | $19.4M | $27.6M | $12.4M |
| Current Assets | $1.3M | $349.2M | $187.2M | $176.8M | $132.8M | $106.0M |
| Total Assets | $150.9M | $398.4M | $350.1M | $305.6M | $242.7M | $191.1M |
| Current Liabilities | $388,507 | $5.8M | $6.8M | $9.1M | $7.6M | $8.0M |
| Total Liabilities | $5.6M | $34.9M | $35.1M | $40.2M | $34.0M | $34.1M |
| Shareholders' Equity | $5.0M | $363.6M | $314.9M | $265.4M | $208.7M | $157.0M |
Nautilus Biotechnology Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$549,570 | -$39.2M | -$45.8M | -$51.7M | -$59.1M | -$50.7M |
| Cash From Investing | -$149.5M | -$139.0M | -$25.7M | -$43.7M | $66.2M | $35.2M |
| Cash From Financing | $151.1M | $327.4M | $562,000 | $368,000 | $1.1M | $214,000 |
| Free Cash Flow | — | -$41.5M | -$48.1M | -$54.2M | -$61.3M | -$52.0M |
Figures from Nautilus Biotechnology's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Nautilus Biotechnology financials page for every line item.
Nautilus Biotechnology Company Profile
| Ticker | NAUT |
|---|---|
| Exchange | Nasdaq |
| Industry | Laboratory Analytical Instruments |
| Headquarters | Seattle, Washington |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001808805 |
Frequently Asked Questions
What was Nautilus Biotechnology's revenue in fiscal 2025?
Nautilus Biotechnology (NAUT) reported revenue of $0 for fiscal 2025.
What is Nautilus Biotechnology's annual revenue history?
Nautilus Biotechnology's annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Nautilus Biotechnology's net income in fiscal 2025?
Nautilus Biotechnology reported net income of -$59.0M for fiscal 2025.
What was Nautilus Biotechnology's earnings per share (EPS) in fiscal 2025?
Nautilus Biotechnology's diluted EPS was -$0.47 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Nautilus Biotechnology generate in fiscal 2025?
Nautilus Biotechnology generated -$52.0M of free cash flow in fiscal 2025.
What was Nautilus Biotechnology's revenue last quarter?
In its most recent reported quarter (2026 Q2), Nautilus Biotechnology reported revenue of $190,000.
How many shares of Nautilus Biotechnology are outstanding?
Nautilus Biotechnology reported a weighted average of 127.1 million basic shares outstanding in 2026 Q2.
What is Nautilus Biotechnology's market cap?
Based on its latest closing price, Nautilus Biotechnology (NAUT) has a market capitalization of about $260.6M.
When does Nautilus Biotechnology's fiscal year end?
Nautilus Biotechnology's fiscal year end, as registered with the SEC, is December 31.
Where is Nautilus Biotechnology headquartered?
Nautilus Biotechnology lists its business address in Seattle, Washington in its SEC filings.